These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6150500)

  • 1. Prolactin-releasing effect of zetidoline, a new neuroleptic agent, in the rat.
    Galliani G; Restelli A; Rosina R; Glässer A
    Pharmacol Res Commun; 1984 Feb; 16(2):117-27. PubMed ID: 6150500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zetidoline, a novel neuroleptic, activates nigral dopaminergic neurons in rats.
    Mereu G; Fanni B; Collu M; Diena A; Glasser A
    Life Sci; 1985 Feb; 36(5):459-64. PubMed ID: 2857469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zetidoline metabolism by rat liver microsomes. Formation of metabolites with potential neuroleptic activity.
    Assandri A; Galliani G; Zerilli L; Tuan G; Tarzia G; Barone D
    Biochem Pharmacol; 1986 May; 35(9):1459-67. PubMed ID: 2871840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations.
    Besser GM; Delitala G; Grossman A; Stubbs WA; Yeo T
    Br J Pharmacol; 1980; 71(2):569-73. PubMed ID: 6110459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of flupenthixol and butaclamol isomers on prolactin secretion in rats.
    Meltzer HY; Paul SM; Fang VS
    Psychopharmacology (Berl); 1977 Jan; 51(2):181-3. PubMed ID: 14352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zetidoline, a specific dopamine antagonist devoid of antiserotonergic activity in rodent brain.
    Pugnetti P; Barone D; Peruzzi M; Restelli A
    Pharmacol Res Commun; 1985 Dec; 17(12):1141-51. PubMed ID: 2869506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
    Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
    J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies--Part I.
    Saletu B; Grünberger J; Linzmayer L; Dubini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):489-95. PubMed ID: 6139346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies: Part II.
    Saletu B; Grünberger J; Linzmayer L; Dubini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):544-51. PubMed ID: 6140228
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between the effects of neuroleptics on prolactin release, mammary stimulation and the vaginal cycle in rats.
    Lotz W; Krause R
    J Endocrinol; 1978 Mar; 76(3):507-15. PubMed ID: 564936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects.
    Gacsályi I; Petöcz L; Fekete MI; Bükkfálvi B; Görgenyi F; Arató M
    Pol J Pharmacol Pharm; 1988; 40(6):613-9. PubMed ID: 2908364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.
    Rubin RT; Hays SE
    Psychoneuroendocrinology; 1980; 5(2):121-37. PubMed ID: 6104835
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential effects of haloperidol decanoate, a long-acting neuroleptic, in behavioral and biochemical tests.
    Oka M; Karasawa T; Ochi Y; Asano K; Terauchi Y; Kadokawa T
    Arch Int Pharmacodyn Ther; 1985 Oct; 277(2):289-302. PubMed ID: 4062440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced haloperidol-induced prolactin stimulation with chronic neuroleptic treatment in the rat.
    Lynch MR; Woo J
    Life Sci; 1991; 49(23):1721-9. PubMed ID: 1943474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that methadone stimulates prolactin release by dopamine receptor blockade.
    Clemens JA; Sawyer BD
    Endocr Res Commun; 1974; 1(4):373-8. PubMed ID: 4462997
    [No Abstract]   [Full Text] [Related]  

  • 17. Elevation of circulating prolactin concentrations may not cause striatal dopamine receptor supersensitivity.
    Rupniak N; Hong M; Mansfield S; Fleminger S; Dyer R; Jenner P; Marsden CD
    Eur J Pharmacol; 1983 Sep; 93(3-4):195-200. PubMed ID: 6139285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
    Apud JA; Masotto C; Ongini E; Racagni G
    Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical and pharmacological activities of zetidoline (DL 308-IT): a new antidopaminergic agent.
    Barone D; Corsico N; Diena A; Restelli A; Glässer A; Rodenghi F
    J Pharm Pharmacol; 1982 Feb; 34(2):129-32. PubMed ID: 6121878
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroendocrine effects of bromperidol.
    Bianchi A; Drago F; Canonico PL; Guarcello V; Carpiniello B; Scapagnini U
    Acta Psychiatr Belg; 1978; 78(1):69-82. PubMed ID: 417559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.